This Phase I study enrolled HLA A2+ patients with pre-treated Stage IIIb (N = 4) and IV (N = 9) NSCLC with tumor expression of MAGE-A3 or A4. This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.